Intervention Review

You have free access to this content

Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis

  1. Arturo J Martí-Carvajal1,*,
  2. Luis H Agreda-Pérez2,
  3. Ivan Solà3

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 11 AUG 2012

DOI: 10.1002/14651858.CD000332.pub3


How to Cite

Martí-Carvajal AJ, Agreda-Pérez LH, Solà I. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD000332. DOI: 10.1002/14651858.CD000332.pub3.

Author Information

  1. 1

    Iberoamerican Cochrane Network, Valencia, Venezuela

  2. 2

    Hospital "Dr. Adolfo Prince Lara", Medicina Interna, Pto. Cabello, Edo. Carabobo, Venezuela

  3. 3

    CIBER Epidemiología y Salud Pública (CIBERESP), Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Catalunya, Spain

*Arturo J Martí-Carvajal, Iberoamerican Cochrane Network, Valencia, Venezuela. arturo.marti.carvajal@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Nordström 1997 {published data only}
  • Nordström D, Lindroth Y, Marsal L, Hafstrom I, Henrich C, Rantapaa-Dahlqvist S, et al. Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis. Rheumatology International 1997;17(2):67-73. [PUBMED: 9266623]
Peeters 1996 {published data only}
  • Peeters HR, Jongen-Lavrencic M, Bakker CH, Vreugdenhil G, Breedveld FC, Swaak AJ. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatology International 1999;18(5-6):201-6. [PUBMED: 10399796]
  • Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomized placebo controlled double blind 52 weeks clinical trial. Annals of the Rheumatic Diseases 1996;55(10):739-44. [PUBMED: 8984939]
Pincus 1990 {published data only}
  • Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris ER, Schnitzer TJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. The American Journal of Medicine 1990;89(2):161-8. [PUBMED: 2200263]

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Arndt 2005 {published data only}
  • Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Moller B. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Annals of Hematology 2005;84(3):159-66. [PUBMED: 15565327]
Birgegard 1991 {published data only}
  • Birgegard G, Gudbjronsson B, Hallgren R, Wide L. Anemia of chronic inflammatory arthritides: treatment with recombinant human erythropoietin. Contributions to Nephrology 1991;88:295-303; discussion 304-5. [PUBMED: 2040192]
Dyjas 2005 {published data only}
  • Dyjas R, Bulanowski M, Ficek R, Witkowicz J, Chudek J, Wiecek A. [Influence of recombinant human erythropoietin (rHuEPO) on plasma levels of selected hormones in females with rheumatoid arthritis] [Wplyw leczenia niedokrwistosci za pomoca ludzkiej erytropoetyny uzyskanej metodt rekombinacji genetycznej (rHuEPO) na stezenie w osoczu wybranych hormonow u kobiet chorych na reumatoidalne zapalenie stawow.]. Polskie Archiwum Medycyny Wewnetrznej 2005;114(2):731-7. [PUBMED: 16808310]
Fantini 1992 {published data only}
  • Fantini F, Gattinara M, Gerloni V, Bergomi P, Cirla E. Severe anemia associated with active systemic-onset juvenile rheumatoid arthritis successfully treated with recombinant human erythropoietin: a pilot study. Arthritis and Rheumatism 1992; Vol. 35, issue 6:724-6. [PUBMED: 1599527]
Goodnough 1997 {published data only}
  • Goodnough LT, Marcus RE. The erythropoietic response to erythropoietin in patients with rheumatoid arthritis. The Journal of Laboratory and Clinical Medicine 1997;130(4):381-6. [PUBMED: 9358076]
Kaltwasser 2001 {published data only}
  • Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. The Journal of Rheumatology 2001;28(11):2430-6. [PUBMED: 11708414]
Kato 1994 {published data only}
  • Kato Y, Takagi C, Tanaka J, Masaki Y, Furuya H. Effect of daily subcutaneous administration of recombinant erythropoietin on chronic anemia in rheumatoid arthritis. Internal Medicine (Tokyo, Japan) 1994;33(4):193-7. [PUBMED: 8069012]
Krantz 1995 {published data only}
  • Krantz SB. Erythropoietin and the anaemia of chronic disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1995;10 Suppl 2:10-7. [PUBMED: 7644100]
Matsuda 2001 {published data only}
  • Matsuda S, Kondo M, Mashima T, Hoshino S, Shinohara N, Sumida S. Recombinant human erythropoietin therapy for autologous blood donation in rheumatoid arthritis patients undergoing total hip or knee arthroplasty. Orthopedics 2001;24(1):41-4. [PUBMED: 11199350]
Means 1989 {published data only}
  • Means RT Jr, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ, et al. Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies. Arthritis and Rheumatism 1989;32(5):638-42. [PUBMED: 2719734]
Mercuriali 1996 {published data only}
  • Mercuriali F. Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. Seminars in Hematology 1996;33(2 Suppl 2):18-20; discussion 21. [PUBMED: 8723576]
Mercuriali 1997 {published data only}
  • Mercuriali F, Inghilleri G, Biffi E, Colotti MT, Vinci A, Sinigaglia L, et al. Comparison between intravenous and subcutaneous recombinant human erythropoietin (Epoetin alfa) administration in presurgical autologous blood donation in anemic rheumatoid arthritis patients undergoing major orthopedic surgery. Vox Sanguinis 1997;72(2):93-100. [PUBMED: 9088076]
  • Mercuriali F, Gualtieri G, Biffi E, Inghilleri G, Colotti M, Vinci A, et al. Intravenous vs subcutaneous erythropoietin for autologous blood donation in anemic rheumatoid arthritis patients. Transfusion Supplement. 1994; Vol. 34.
  • Mercuriali F, Gualtieri G, Inghilleri G, Biffi E, Vinci A, Colotti M, et al. Erythropoietin and autologous blood donation in surgical rheumatoid arthritis patients with anemia. Transfusion Abstract. Florida, 1993; Vol. 33, issue 28.
Murphy 1994 {published data only}
  • Murphy EA, Bell AL, Wojtulewski J, Brzeski M, Madhok R, Capell HA. Study of erythropoietin in treatment of anaemia in patients with rheumatoid arthritis. BMJ 1994;309(6965):1337-8. [PUBMED: 7866082]
Pettersson 1993a {published data only}
  • Pettersson T, Rosenlof K, Friman C, Mickos A, Teppo A M, Fyhrquist F. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation. Scandinavian Journal of Rheumatology 1993;22(4):188-93. [MEDLINE: 8356412]
Saikawa 1994 {published data only}
  • Saikawa I, Hotokebuchi T, Arita C, Inaba S, Shuto T, Tsutsui H, et al. Autologous blood transfusion with recombinant erythropoietin treatment. 22 arthroplasties for rheumatoid arthritis. Acta Orthopaedica Scandinavica 1994;65(1):15-9. [PUBMED: 8154276]
Salvarani 1991 {published data only}
  • Salvarani C, Lasagni D, Casali B, Macchioni P, Boiardi L, Rossi F, et al. Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease. The Journal of Rheumatology 1991;18(8):1168-71. [PUBMED: 1941817]
Swaak 1994 {published data only}
  • Swaak AJ, Nieuwenhuizen C, Vreugdenhil G. Recombinant human erythropoietin (r-hu-EPO) treatment in patients with rheumatoid arthritis and anaemia of chronic disease (ACD). Clinical and Experimental Rheumatology 1994; Vol. 12, issue 5:577. [PUBMED: 7842542]
Takashina 1990 {published data only}
  • Takashina N, Kondo H, Kashiwazaki S. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. The Journal of Rheumatology 1990;17(7):885-7. [PUBMED: 2213753]
Tauchi 1990 {published data only}
  • Tauchi T, Ohyashiki JH, Fujieda H, Lin KY, Ohyashiki K, Toyama K. Correction of anaemia in rheumatoid arthritis by recombinant human erythropoietin. British Journal of Rheumatology 1990; Vol. 29, issue 3:235-6. [PUBMED: 2357513]
Vreugdenhil 1990 {published data only}
Vreugdenhil 1992 {published data only}
  • Vreugdenhil G, Manger B, Nieuwenhuizen C, Feelders RA, van Eijk HG, Swaak AJ. Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis. Annals of Hematology 1992;65(6):265-8. [PUBMED: 1457588]

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Agarwal 2009
Al-Ghamdi 2009
  • Al-Ghamdi A, Attar SM. Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Annals of Saudí Medicine 2009;29:189-93. [PUBMED: 19448378]
Alten 2011
  • Alten R, Pohl C, Choy EH, Christensen R, Furst DE, Hewlett SE, et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. The Journal of Rheumatology 2011; Vol. 38, issue 8:1745-50. [PUBMED: 21807796]
Andrews 2007
Andrews 2008
Arnett 1988
Baer 1997
Balshem 2011
  • Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6. [PUBMED: 21208779]
Bartlett 2012
  • Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Annals of the Rheumatic Diseases Jul 6. [Epub ahead of print]. [PUBMED: 22772326]
Basch 2012
  • Basch E,  Aronson N,  Berg A,  Flum D,  Gabriel S,  Goodman SN, et al. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636-40. [PUBMED: 22511692]
Bennet 2008
  • Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24. [PUBMED: 18314434 ]
Bingham 2011
  • Bingham CO 3rd, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, et al. Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop. The Journal of Rheumatology 2011; Vol. 38, issue 8:1751-8. [PUBMED: 21807797]
Blumenauer 2002
  • Blumenauer BBTB, Judd M, Wells GA, Burls A, Cranney A, Hochberg MC, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785]
Blumenauer 2003
  • Blumenauer BBTB, Cranney A, Burls A, Coyle D, Hochberg MC, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004525]
Capocasale 2008
Cartwright 1966
  • Cartwright GE. The anemia of chronic disorders. Seminars in Hematology 1966;3:351-75. [PUBMED: 5341723]
Cases 2003
Clarke 2007
Coussons 2005
  • Coussons PJ, Baig S, Fanutti C, Grant R. Novel tissue remodelling roles for human recombinant erythropoietin. Biochemical Society Transactions 2005;33 (Pt 5):1129-30. [PUBMED: 16246063]
Cronstein 2007
  • Cronstein BN. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2007;65 (Suppl 1):11-5. [PUBMED: 17708739 ]
Dayer 2010
Demirag 2009
  • Demirag MD, Haznedaroglu S, Sancak B, Konca C, Gulbahar O, Ozturk MA, et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Internal Medicine 2009;48:421-6. [PUBMED: 19293540]
FDA 2008a
  • Food, Drug Administration. EPOGEN (epoetin alfa) solution. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9169 [Accessed January 29, 2010].
FDA 2008b
  • Food, Drug Administration. Erythropoiesis Stimulating Agents: Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110251.htm March 07, 2008 (Accessed Jan 29, 2010).
Fonseca 2009
Furst 2009
  • Furst DE, Chang H, Greenberg JD, Ranganath VK, Reed G, Ozturk ZE, et al. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Clinical and Experimental Rheumatology 2009;27:560-6. [PUBMED: 19772785]
Gabriel 2012
  • Gabriel SE, Normand SL. Getting the methods right - the foundation of patient-centered outcomes research. The New England Journal of Medicine 2012 Jul 25 [Epub ahead of print]. [PUBMED: 22830434]
Ganz 2009
Glaspy 2009
GRADEPro 2008
  • Brozek J, Oxman A, Schünemann H. GRADEpro. 3.2 for Windows 2008.
Grassi 1998
  • Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. European Journal of Radiology 1998;27 (Suppl 1):18-24. [PUBMED: 9652497]
Gudbjörnsson 1992
  • Gudbjörnsson B, Hällgren R, Wide L, Birgegård G. Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Annals of Rheumatic Diseases 1992;51:747-52. [PUBMED: 1616357]
Guyatt 2011a
  • Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94. [PUBMED: 21195583]
Guyatt 2011b
  • Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400. [PUBMED: 21194891]
Guyatt 2011c
  • Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15. [PUBMED: 21247734]
Guyatt 2011d
  • Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82. [PUBMED: 21802904]
Guyatt 2011e
  • Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93. [PUBMED: 21839614]
Guyatt 2011f
  • Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302. [PUBMED: 21803546]
Guyatt 2011g
  • Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10. [PUBMED: 21802903]
Guyatt 2011h
  • Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6. [PUBMED: 21802902]
Han 2007
  • Han C, Rahman MU, Doyle MK, Bathon JM, Smolen J, Kavanaugh A, et al. Association of anemia and physical disability among patients with rheumatoid arthritis. Journal of Rheumatology 2007;34:2177-82. [PUBMED: 17937474]
Hershman 2009
  • Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. Journal of the National Cancer Institute 2009;101:1633-41. [PUBMED: 19903808 ]
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.5 [updated September 29th, 2009]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hochberg 1988
Hochberg 2008
  • Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Current Medical Research and Opinion 2008;24:469-80. [PUBMED: 18179735 ]
Hopewell 2010
  • Hopewell S, Clarke M, Higgins JPT (editors). Core reporting of outcomes in effectiveness trials. Cochrane Methods. Cochrane Database of Systematic Reviews 2010; Vol. Suppl 1:1-29. [: ISSN 2044-4702]
Ibbotson 2001
Imboden 2009
Ioannidis 2004
  • Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8. [PUBMED: 15545678]
Ioannidis 2010
Jaworski 2008
  • Jaworski J, Maslinski W, Pazdur J, Sliwinska-Stanczyk P, Kaminska-Tchorzewska E, Jung L, et al. Decreased expression of integrins by hematopoietic cells in patients with rheumatoid arthritis and anemia: relationship with bone marrow cytokine levels. Journal of Investigational Allergology & Clinical Immunology 2008;18:17-21. [PUBMED: 18361097]
Jayaranee 2009
Kirkham 2010
  • Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomized controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [PUBMED: 20156912]
Kirwan 2007
  • Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. Journal of Rheumatology 2007;34:1174-7. [PUBMED: 17477482]
Kishimoto 2006
Krantz 1990
Lee 2001
Lee 2009
Macdougall 2005
Masson 2011
Maxwell 2009
McInnes 2011
Means 1995
Mertens 2009
Michaud 2007
Moher 2010
  • Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials. BMJ 2010;340:c869. [PUBMED: 20332511]
Moreland 2009
  • Moreland LW, Curtis JR. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Seminars in Arthritis and Rheumatism 2009;39:132-43. [PUBMED: 19022481]
Muñoz 2009
Navarro-Sarabia 2005
Nebeker 2004
  • Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of Internal Medicine 2004;140:795-801. [PUBMED: 15148066]
Nemeth 2003
Nemeth 2004
  • Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation 2004;113:1271-6. [PUBMED: 15124018]
Nicolaisen 2008
  • Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. Journal of Rheumatology 2008;35:380-6. [PUBMED: 18260177]
Papadaki 2002
  • Papadaki HA, Kritikos HD, Gemetzi C, Koutala H, Marsh JC, Boumpas DT, et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002;99:1610-9. [PUBMED: 11861275]
Paulus 1990
  • Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis and rheumatism 1990;33(4):477-84. [PUBMED: 2109613]
PCORI 2012
  • Patient-Centered Outcomes Research Institute (PCORI). Preliminary draft methodology report: “Our questions, our decisions: Standards for patient-centered outcomes research”. http://www.pcori.org/assets/Preliminary-Draft-Methodology-Report.pdf (accessed 27 July 2012):1-61.
Pettersson 1993
  • Pettersson T, Rosenlöf K, Friman C, Mickos A, Teppo AM, Fyhrquist F. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation. Scandinavian Journal of Rheumatology 193;22:188-93. [PUBMED: 8356412]
Pettersson 1994
  • Pettersson T, Rosenlöf K, Laitinen E, Tenhunen R. Effect of exogenous erythropoietin on haem synthesis in anaemic patients with rheumatoid arthritis. British Journal of Rheumatology 1994;33:526-9. [PUBMED: 8205399]
Porta 2008
  • Porta M. A Dictionary of Epidemiology. New York: Oxford University Press, 2008. [: ISBN 978-0-19-531449-6]
Raj 2009
RevMan 2011
  • The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2011.
Roy 2005
Ruiz Garcia 2011
Sasu 2010
  • Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, et al. Anti-hepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010;115(17):3616-24. [PUBMED: 20053755]
Singh 2009
  • Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2]
Singh 2010a
  • Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008341]
Singh 2010b
Singh 2011
Smith 1992
  • Smith MA, Knight SM, Maddison PJ, Smith JG. Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages. Annals of the Rheumatic Diseases 1992;51:753-7. [PUBMED: 1616358]
Sterne 2011
  • Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ 2011;343:d4002. [PUBMED: 21784880]
Theurl 2009
  • Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277-86. [PUBMED: 19293425 ]
Tugwell 2007
Turesson 2003
  • Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Annals of the Rheumatic Diseases 2003;62:722-7. [PUBMED: 12860726]
Unger 2010
van der Putten 2008
  • van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nature Clinical Practice. Nephrology 2008;4(1):47-57. [PUBMED: 18094727]
Vreugdenhil 1992a
Vreugdenhil 1992b
  • Vreugdenhil G, Manger B, Nieuwenhuizen C, Feelders RA, van Eijk HG, Swaak AJ. Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis. Annals of Hematology 1992;65:265-8. [PUBMED: 1457588]
Weiss 2002
Weiss 2009
WHO 2008
  • de Benoist B, McLean E, Egli I, Cogswell M, editors. Worldwide prevalence of anaemia 1993–2005 : WHO global database on anaemia. Geneva: World Health Organization, 2008. [: ISBN 978 92 4 159665 7]
Wilson 2004
  • Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. American Journal of Medicine 2004;116(Suppl 7A):50-7. [PUBMED: 15050886 ]
Wu 2003
Young 2007
Zhang 2009
  • Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2009:207-14. [PUBMED: 20008200]
Zhu 2000
  • Zhu Y, Ye D, Huang Z. The correlation of cytokines TNF alpha, IFN-gamma, Epo with anemia in rheumatoid arthritis. Zhonghua Xueyexue Zazhi 2000;21:587-90. [PUBMED: 11225250 ]